Alizapride

drugbox
IUPAC_name = "N"- [(1-allylpyrrolidin-2-yl)methyl] -6-methoxy-
1"H"-benzotriazole-5-carboxamide

---

CAS_number = 59338-93-1
ATC_prefix = A03
ATC_suffix = FA05
PubChem = 43008
DrugBank =
C=16|H=21|N=5|O=2
molecular_weight = 315.37 g/mol
bioavailability =
protein_bound =
metabolism =
elimination_half-life = 3 hours
excretion = Renal
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration = Oral, intramuscular, intravenous

Alizapride is a dopamine antagonist with prokinetic and antiemetic effects used in the treatment of nausea and vomiting, including postoperative nausea and vomiting. It is structurally related to metoclopramide. [cite journal |author=Bleiberg H, Gerard B, Dalesio O, Crespeigne N, Rozencweig M |title=Activity of a new antiemetic agent: alizapride. A randomized double-blind crossover controlled trial |journal=Cancer Chemother Pharmacol |volume=22 |issue=4 |pages=316–20 |year=1988 |pmid=3048762 |doi=]

Alizapride is marketed under various trade names including Plitican, Superan and Vergentan. [fr icon cite web | url = http://www.biam2.org/www/Sub4814.html | title = Alizapride Chlorhydrate | date = June 2 1997 | accessdate = 2007-08-14 | publisher = BIAM]

References